Law360, New York (August 08, 2011, 9:48 PM ET) -- While U.S. health care regulators have backed down from their bold threat to ban Forest Laboratories Inc.'s CEO from contracting with the government in the wake of the drugmaker's alleged off-label marketing, the relief may be short-lived, defense attorneys fear, as regulators remain poised to bring other such cases.
During the time Forest was fined $313 million in September for off-label marketing of Celexa and other violations, controversy broke out after the U.S. Department of Health and Human Services threatened Forest CEO Howard Solomon with exclusion...
Forest Decision Does Little To Remove Exclusion Threat
To view the full article, take a free trial now.
